https://www.thebodypro.com/category/tenofovir-tdf-viread/tag/conference-coverage

The Latest

Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

Christoph D. Spinner

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

Promo Image

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study Img

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study

The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults Img

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults

Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.

Promo Image

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older Img

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.

Tenofovir-Containing ART Reduces Bone Mineral Density in Breast-Feeding Women: Results From IMPAACT P1084s Img

Tenofovir-Containing ART Reduces Bone Mineral Density in Breast-Feeding Women: Results From IMPAACT P1084s

Tenofovir DF-containing ART decreases bone mineral density in HIV-positive, breast-feeding women, according to findings presented at the 8th International Workshop on HIV Paediatrics.

Tenofovir Levels in Blood 4-Fold Higher With TAF Than TDF Img

Tenofovir Levels in Blood 4-Fold Higher With TAF Than TDF

Tenofovir levels in the blood were four times higher with tenofovir alafenamide (TAF) than with tenofovir disoproxil fumarate (TDF) in a randomized, double-blind switch study.